CSIMarket Company Name, Ticker, Competitors, else..
 
Kymera Therapeutics Inc   (NASDAQ: KYMR)
 
Price: $115.4300 $-1.04 -0.893%
Day's High: $120.66500091552734 Week Perf: -2.7 %
Day's Low: $ 113.18 30 Day Perf: 6.31 %
Volume (M): 765,342 52 Wk High: $ 130.05
Volume (M$): $ 0 52 Wk Avg: $82.66
Open: $115.34 52 Wk Low: $43.74



 Market Capitalization (Millions $) 11,333
 Shares Outstanding (Millions) 98
 Employees 238
 Revenues (TTM) (Millions $) 105
 Net Income (TTM) (Millions $) -300
 Cash Flow (TTM) (Millions $) -192
 Capital Exp. (TTM) (Millions $) 1

Business Description


Kymera Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing targeted protein degradation therapies to address various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. The company's proprietary platform enables the selective degradation of disease-causing proteins, providing a novel approach to drug development. By harnessing the body's natural protein degradation system, Kymera aims to create highly specific and effective treatments for previously challenging conditions.


   Company Address: 500 North Beacon Street Watertown 2472 MA
   Company Phone Number: 285-5300   Stock Exchange / Ticker: NASDAQ KYMR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -10.69%    
BCRX   -11.24%    
BIIB   -2.46%    
CCCC   -11.11%    
EXEL        2.53% 
GILD   -2.85%    
• View Complete Report
   



Clinical Study

Kymera Therapeutics Gears Up for Phase 1 Results What’s Next for KT-621

Published Sat, May 31 2025 10:05 AM UTC

Kymera Therapeutics, a biotechnology company focused on innovative therapeutics, is poised to share crucial updates about its lead product candidate, KT-621, with the upcoming announcement of Phase 1 trial results. Scheduled for June 2, 2025, at 8:00 a.m. ET, the company will host a video webcast to discuss these findings, providing insights into the safety and pharmacokinet...
Management Changes

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Published Wed, Apr 9 2025 11:00 AM UTC

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer Amidst Milestones and Financial RealitiesKymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering biopharmaceutical company headquartered in Watertown, Massachusetts, has recently announced the appointment of Noah Goodman, M.B.A. as its new Chief Business Officer. This strategic move comes at a crucial junctu...
Management Announcement

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Published Tue, Jan 14 2025 12:00 PM UTC

Kymera Therapeutics: Pioneering a New Era in Oral Immunology Amidst Financial ChallengesOverview of Facts:1. Recent FDA Clearance: Kymera Therapeutics received FDA clearance for its Investigational New Drug (IND) application for KT-621, marking a significant milestone as the first oral STAT6 degrader targeting Th2-mediated diseases. 2. Clinical Development: The Phase 1 tr...
Clinical Study

Kymera Therapeutics Secures FDA Clearance for First-in-Class Oral STAT6 Degrader KT-621, Showcasing Promising Activit...

Published Wed, Oct 9 2024 11:00 AM UTC

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class Oral STAT6 Degrader Kymera Therapeutics, a biotechnology company at the forefront of targeted protein degradation, has made significant strides in its drug development pipeline following the recent announcement of FDA clearance for its Investigational New Drug (IN...
Clinical Study

KT-621 Heralding a New Epoch in Oral STAT6 Degradation Amidst Fiscal Adversity,

Published Wed, Sep 25 2024 11:00 AM UTC

Quarterly Edition: Autumn 2023 Kymera Therapeutics Unveils Preclinical Insights on KT-621: A Pioneer in Oral STAT6 Degradation By CSIMarket.com: Dr. Henry M. Archibald In the grand tradition of pharmaceutical innovation, Kymera Therapeutics has presented, at the distinguished EADV Congress, preclinical findings on a novel and promising agent, KT-621. This molecule, imbued...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 28.36
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 107.93
Price to Sales (Expected) -
Price to Book 7.51
PEG (TTM) 0.42

Financial Strength Current
Quick Ratio 69.6
Working Capital Ratio 70.24
Leverage Ratio (MRQ) 0.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 4.07 $
Revenues (TTM) 1.07 $
Cash Flow (TTM) -
Cash 50.56 $
Book Value 15.37 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 441,176
Net Income per Employee (TTM) -1,258,828
Receivable Turnover Ratio (TTM) 10.5
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -116.32 %
Net Margin (MRQ) -94.17 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Kymera Therapeutics Inc's Segments

  Kymera Therapeutics Inc Outlook

On February 22 2024 the Kymera Therapeutics Inc provided following guidance

Kymera Therapeutics Inc. reported its financial results for the fourth quarter and full year of 2023, as well as provided a business update. The company highlighted the progress of its KT-474/SAR444656 (IRAK4) Phase 2 program, which is advancing in the treatment of both Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). Data from this program is expected to be available in the first half of 2025. This development marks a significant milestone for Kymera Therapeutics as it continues to innovate and bring potential therapeutic options to patients with these challenging conditions. The company remains committed to advancing research and development efforts to address unmet medical needs in the field of p...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.